A six month comparison of toleration and efficacy of sertraline and fluoxetine treatment of major depression

Latimer, Paul; Ravindran, Arun; Bernatchez, Julien; Fournier, Jean‐Pascal; Gojer, Julian; Barratt, KH; Buttars, Jennifer A.

doi:10.1016/0924-977x(96)87876-x

Cited by 7 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although some previous studies have reported changes in quality of life from the open-label phase baseline to end of double-blind continuation treatment (Latimer et al, 1996;berg-Wistedt et al, 2000), only one study has examined the change in quality of life from the end of acute treatment to the end of continuation phase treatment. This study compared sertraline and imipramine as continuation treatments, and found no difference between treatments (and little change) in change in quality of life from week 12 (end of acute phase) to week 28 (end of continuation) (Koran et al, 2001).…”

Section: Discussionmentioning

confidence: 97%

A placebo-controlled, randomized withdrawal study of sertraline for major depressive disorder in Japan

Kamijima

Burt²,

Cohen³

et al. 2006

International Clinical Psychopharmacology

View full text Add to dashboard Cite

The objective of this double-blind, placebo-controlled, multicentre randomized withdrawal study was to evaluate the efficacy and tolerability of sertraline for 16 weeks in treating Japanese patients with major depressive disorder (MDD) who had achieved a response to 8 weeks of sertraline treatment. Patients (n=361) were initially treated with 8 weeks of open-label sertraline treatment followed by 16 weeks of double-blind treatment with either sertraline (50-100 mg/day) or placebo. Responders during the open-label phase were eligible to be entered into the double-blind phase. A total of 235 patients (65.1%) were entered to the double-blind phase and randomly assigned to receive sertraline (n=117) or placebo (n=118). A significantly (P=0.016) lower relapse rate was found for sertraline (8.5%) compared to placebo (19.5%) during the double-blind phase. Examination of time-to-relapse showed that the relapse free rate curve was significantly higher for sertraline (log-rank test, P=0.026) than placebo. Mean changes from beginning to end of the double-blind phase on measure of depressive symptoms, quality of life and global improvement also significantly favoured sertraline over placebo. Sertraline was well-tolerated, with similar adverse events as found in previous studies. These results confirm the efficacy of sertraline in preventing the relapse of MDD in Japanese patients.

show abstract

Section: Discussionmentioning

confidence: 97%

A placebo-controlled, randomized withdrawal study of sertraline for major depressive disorder in Japan

Kamijima

Burt²,

Cohen³

et al. 2006

International Clinical Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Indeed, studies have shown that sertraline does provide some of these advantages relative to other SSRIs (Hindmarch et al, 1990;Meara et al, 1995;Thakore et al, 1995;Van Moffaert et al, 1995;Bisserbe et al, 1996;Latimer et al, 1996;Newhouse et al, 1996;Price et al, 1996;Shulman et al, 1996;Zanardi et al, 1996;Hauser and Zesiewicz, 1997;Lane, 1997;MacKay et al, 1997;Mulholland et al, 1997;Waldinger, 1997;Agren et al, 1998;Lane, 1998).…”

Section: Pharmacologymentioning

confidence: 96%

Selective serotonin reuptake inhibitors in affective disorders — I. Basic pharmacology

Goodnick¹,

1998

View full text Add to dashboard Cite

The selective serotonin reuptake inhibitors (SSRIs), citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline, are the result of rational research to find drugs that were as effective as the tricyclic antidepressants but with fewer safety and tolerability problems. The SSRIs selectively and powerfully inhibit serotonin reuptake and result in a potentiation of serotonergic neurotransmission. The property of potent serotonin reuptake appears to give a broad spectrum of therapeutic activity in depression, anxiety, obsessional and impulse control disorders. However, despite the sharing of the same principal mechanism of action, SSRIs are structurally diverse with clear variations in their pharmacodynamic and pharmacokinetic profiles. The potency for serotonin reuptake inhibition varies amongst this group, as does the selectivity for serotonin relative to noradrenaline and dopamine reuptake inhibition. The relative potency of sertraline for dopamine reuptake inhibition differentiates it pharmacologically from other SSRIs. Affinity for neuroreceptors, such as sigma1, muscarinic and 5-HT 2c , also differs widely. Furthermore, the inhibition of nitric oxide synthetase by paroxetine, and possibly other SSRIs, may have significant pharmacodynamic effects. Citalopram and fluoxetine are racemic mixtures of different chiral forms that possess varying pharmacokinetic and pharmacological profiles. Fluoxetine has a long acting and pharmacologically active metabolite. There are important clinical differences among the SSRIs in their pharmacokinetic characteristics. These include differences in their half-lives, linear versus non-linear pharmacokinetics, effect of age on their clearance and their potential to inhibit drug metabolising cytochrome P450 (CYP) isoenzymes. These pharmacological and pharmacokinetic differences underly the increasingly apparent important clinical differences amongst the SSRIs.

show abstract

“…Equal or greater global improvement was also observed in patients taking sertraline compared with fluoxetine after 24 weeks of continued therapy (130,238). Persons in a double-blind multicenter, 24-week comparative trial demonstrated equal tolerability of citalopram and sertraline (59).…”

Section: Major Depressionmentioning

confidence: 96%

“…In the treatment of depression with melancholic features, sertraline had greater efficacy compared with fluoxetine (72,130), paroxetine (251), and mianserin (142) and equivalent efficacy to the TCAs, including amitriptyline (198) and clomipramine (135).…”

Section: Major Depressionmentioning

confidence: 99%

The Selective Serotonin Reuptake Inhibitor Sertraline: Its Profile and Use in Psychiatric Disorders

2001

View full text Add to dashboard Cite

The naphthylamine derivative sertraline is a potent and selective inhibitor of serotonin reuptake into presynaptic terminals. Sertraline has a linear pharmacokinetic profile and a half-life of about 26 h. Its major metabolite, desmethylsertraline does not appear to inhibit serotonin reuptake. Sertraline mildly inhibits the CYP2D6 isoform of the cytochrome P450 system but has little effect on CYP1A2, CYP3A3/4, CYP2C9, or CYP2C19. It is, however, highly protein bound and may alter blood levels of other highly protein bound agents. Sertraline is a widely used serotonin reuptake inhibitor that has been shown to have both antidepressant and antianxiety effects. Many clinical trials have demonstrated its efficacy in depression compared with both placebo and other antidepressant drugs. Its efficacy has also been demonstrated in randomized, controlled trials of patients with obsessive-compulsive disorder, panic disorder, social phobia, and premenstrual dysphoric disorder. In short-term, open-label studies it has appeared efficacious and tolerable in children and adolescents and in the elderly, and data are positive for its use in pregnant or lactating women. Typical side effects include gastrointestinal and central nervous system effects as well as treatment-emergent sexual dysfunction; withdrawal reactions may be associated with abrupt discontinuation of the agent. The safety profile of sertraline in overdose is very favorable. Sertraline's efficacy for both mood and anxiety disorders, relatively weak effect on the cytochrome P450 system, and tolerability profile and safety in overdose are factors that contribute to make it a first-line agent for treatment in both primary and tertiary care settings.

show abstract

A six month comparison of toleration and efficacy of sertraline and fluoxetine treatment of major depression

Cited by 7 publications

References 0 publications

A placebo-controlled, randomized withdrawal study of sertraline for major depressive disorder in Japan

A placebo-controlled, randomized withdrawal study of sertraline for major depressive disorder in Japan

Selective serotonin reuptake inhibitors in affective disorders — I. Basic pharmacology

The Selective Serotonin Reuptake Inhibitor Sertraline: Its Profile and Use in Psychiatric Disorders

Contact Info

Product

Resources

About